首页> 外文期刊>AACN advanced critical care >Left ventricular assist device driveline infections: The Achilles' heel of destination therapy
【24h】

Left ventricular assist device driveline infections: The Achilles' heel of destination therapy

机译:左心辅助设备动力传动系统感染:目的地疗法的致命弱点

获取原文
获取原文并翻译 | 示例
           

摘要

Heart failure is a chronic progressive disease that affects millions of people in the United States. Although medical management of heart failure has helped improve quality of life and survival, end-stage heart failure ultimately requires a heart transplant or long-term left ventricular assist device (LVAD) support. With more patients awaiting transplant, the demand for hearts outweighs the supply of donor hearts. The use of LVADs is increasing in patients with advanced heart failure as a treatment option for those awaiting a heart transplant or as a long-term solution if they are ineligible for a transplant. Although the LVAD is a marvel of modern medicine, infection is a cause of concern because today's LVADs are powered externally through a percutaneous driveline that can be a major source of infection.
机译:心力衰竭是一种慢性进行性疾病,在美国影响数百万人。尽管心力衰竭的医学管理有助于改善生活质量和生存,但终末期心力衰竭最终需要心脏移植或长期的左心室辅助设备(LVAD)支持。随着更多患者等待移植,对心脏的需求超过了供体心脏的供应。患有晚期心力衰竭的患者越来越多地使用LVAD作为等待心脏移植的患者的治疗选择,或者将其作为不适合移植的长期解决方案。尽管LVAD是现代医学的奇迹,但感染仍然令人担忧,因为当今的LVAD是通过可能是主要感染源的经皮传动系统从外部提供动力的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号